Search research articles
Contact Us
Filters
Showing results (121-130 of 134) with videos related to
Page
of 14
Sort By:
JAMA Oncology
|
October 7, 2017
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials
Aziz Zaanan, Qian Shi, Julien Taieb, et al.
Cancers
|
August 26, 2022
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
Valentina Russo, Eleonora Lallo, Armelle Munnia, et al.
JCO Precision Oncology
|
September 14, 2020
Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials
Aziz Zaanan, Qian Shi, Julien Taieb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 11, 2019
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
Ugo De Giorgi, Giuseppe Procopio, Diana Giannarelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2009
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3
Eric Van Cutsem, Roberto Labianca, György Bodoky, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
November 30, 2018
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program
Marina Chiara Garassino, Lucio Crinò, Annamaria Catino, et al.
Cancers
|
June 22, 2023
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma
Gabriele Perrone, Luigi Rigacci, Sara Urru, et al.
JAMA Oncology
|
November 24, 2017
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status
Julien Taieb, Hampig Raphael Kourie, Jean-François Emile, et al.
Clinical Pharmacology and Therapeutics
|
October 20, 2018
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice
Giuseppe Toffoli, Federico Innocenti, Jerry Polesel, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 10, 2013
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial
Pierpaolo Correale, Cirino Botta, Maria S Rotundo, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 134) with videos related to
Sort By:
Page
of 14
JAMA Oncology
|
October 7, 2017
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials
Aziz Zaanan, Qian Shi, Julien Taieb, et al.
Cancers
|
August 26, 2022
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
Valentina Russo, Eleonora Lallo, Armelle Munnia, et al.
JCO Precision Oncology
|
September 14, 2020
Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials
Aziz Zaanan, Qian Shi, Julien Taieb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 11, 2019
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
Ugo De Giorgi, Giuseppe Procopio, Diana Giannarelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2009
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3
Eric Van Cutsem, Roberto Labianca, György Bodoky, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
November 30, 2018
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program
Marina Chiara Garassino, Lucio Crinò, Annamaria Catino, et al.
Cancers
|
June 22, 2023
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma
Gabriele Perrone, Luigi Rigacci, Sara Urru, et al.
JAMA Oncology
|
November 24, 2017
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status
Julien Taieb, Hampig Raphael Kourie, Jean-François Emile, et al.
Clinical Pharmacology and Therapeutics
|
October 20, 2018
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice
Giuseppe Toffoli, Federico Innocenti, Jerry Polesel, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 10, 2013
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial
Pierpaolo Correale, Cirino Botta, Maria S Rotundo, et al.
Page
of 14